Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lixte Biotechnology Holdings ( (LIXT) ) has issued an update.
On September 3, 2025, LIXTE Biotechnology Holdings announced the appointment of Lourdes Felix and Guy Primus to its Board of Directors and Peter Stazzone as the new Chief Financial Officer. The company also relocated its corporate headquarters to Boca Raton, Florida, aiming to enhance operational efficiency and shareholder value. These strategic changes are expected to strengthen LIXTE’s leadership team and support its mission to develop effective cancer therapies, while the relocation is intended to reduce costs and improve business operations.
More about Lixte Biotechnology Holdings
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing new cancer therapies. The company is pioneering a new class of cancer therapy that enhances chemotherapy and immunotherapy, with its lead compound, LB-100, currently in proof-of-concept clinical trials for various cancers.
Average Trading Volume: 2,121,183
Technical Sentiment Signal: Hold
Current Market Cap: $18.88M
For a thorough assessment of LIXT stock, go to TipRanks’ Stock Analysis page.